Freestone Capital Holdings’s Arcturus Therapeutics ARCT Stock Holding History

Freestone Capital Holdings’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$125K	Hold	18,655	–	–	﹤0.01%	587
2026 Q1	$144K	Hold	18,655	–	–	﹤0.01%	526
2025 Q4	$114K	Hold	18,655	–	–	﹤0.01%	533
2025 Q3	$344K	Hold	18,655	–	–	0.01%	404
2025 Q2	$243K	Hold	18,655	–	–	0.01%	397
2025 Q1	$198K	Hold	18,655	–	–	0.01%	425
2024 Q4	$317K	Hold	18,655	–	–	0.01%	345
2024 Q3	$433K	Buy	18,655 +200	+1%	+$4.28K	0.01%	312
2024 Q2	$449K	Buy	+18,455	New	+$560K	0.02%	314

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Freestone Capital Holdings's ARCT Position: Q2 2026 in Review

Freestone Capital Holdings held its Arcturus Therapeutics (ARCT) position steady in Q2 2026 at 18,655 shares worth $125K. The position accounts for ﹤0.01% of the portfolio, ranked #587.

Freestone Capital Holdings first reported a position in ARCT in Q2 2024 and has held it in 9 quarters since. The position peaked at $449K in Q2 2024. 136 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

Freestone Capital Holdings held 18,655 shares of Arcturus Therapeutics worth $125K as of Q2 2026.
Freestone Capital Holdings left its Arcturus Therapeutics share count unchanged in Q2 2026.
Arcturus Therapeutics made up ﹤0.01% of Freestone Capital Holdings's portfolio in Q2 2026, its #587 holding.
Freestone Capital Holdings first reported a position in Arcturus Therapeutics in Q2 2024 and has held it in 9 quarters since.
Freestone Capital Holdings's Arcturus Therapeutics position peaked at $449K in Q2 2024.
136 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on Freestone Capital Holdings's 13F filing for Q2 2026, filed 31 Jul 2026.